Clinical Trial Update: An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women With Low Bone Mineral Density [Phase 3]

View source ↗

Summary

Open-label, single-arm Phase 3 extension study assessing the long-term safety of denosumab in postmenopausal women with low bone mineral density.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• Prolia (denosumab)

Snippet

Sponsor: Amgen | Conditions: Low Bone Mineral Density | Phase 3 | Status: COMPLETED | Results posted: 2013-07-30